Analysis of VEGF antibody technology patents of roche
ZHANG Chi1, ZHANG Yinghui2
1. Pharmacy and Biotech Examination Department, The Patent Office, State Intellectual Property Office of the P R C, Beijing 100088, China;
2. Patent Examination Administration Departmeng, The Patent Office, State Intellectual Property Office of the P R C, Beijing 100088, China
Abstract：This paper analyzes the technical development route of bevacizumab and ranibizumab based on the vascular endothelial growth factor (VEGF) antibody related patent applications of Roche. The layout in China of the VEGF related patents of Roche is also analyzed. Based on the above analyses, the future trends and directions of the technical research and development of VEGF antibody technology are predicted.
[1] Ferrara N, Hillan K J, Gerber H P, et al.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J].Nature Re-views Drug Discovery, 2004, 3(5): 391-400.
[2] Steinbrook R.The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration[J].New England Journal of Medi-cine, 2006, 355(14): 1409-1412.
[3] 吴炜霖, 仲人前.人源化抗体的演进发展及应用现状[J].现代免疫学.2009, 29(4):337-340.Wu Weilin, Zhong Renqian.Development and application of humanized antibody[J].Current Immunology.2009, 29(4):337-340.
[4] Aiello L P, Avery R L, Arrigg P G, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other reti-nal disorders[J].New England Journal of Medicine, 1994, 331(22): 1480-1487.
2016, Vol. 34 
